The Global Health Body Sounds Warning Over Critical Lack of Weight-Loss Injections
Fewer than 10% of patients that would benefit from GLP-1 drugs such as Wegovy have access to them, states the WHO as it releases its initial guidance on the drugs.
Considering more than one billion individuals worldwide currently obese, it is urging increased and just availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our latest guidance recognises that obesity is a long-term condition that can be managed with thorough and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the treatments that can assist patients in reducing significant body mass, explains the body.
GLP-1 Therapy Scarcity
Even in the present best projected case, the production of such drugs could only cover around 100 million people – fewer than 10% of the global need, as stated by the WHO.
The guideline urges governments and firms to widen access, via strategies such as patent sharing.
The intellectual property rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Jabs Function
The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people reduce food intake.
People usually see weight reduction within a few weeks of beginning the regular doses.
Studies points to users may regain a significant portion a year later of discontinuing the drug, when their usual food cravings return.
To be above a healthy weight elevates your chance for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight affects individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.